{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This study examined the efficacy and safety of the bupivacaine implant (300 mg) compared with placebo for postsurgical pain after abdominoplasty."
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In this double-blind, placebo-controlled study, patients undergoing abdominoplasty were randomized to three 100 mg bupivacaine implants or three placebo collagen implants, in a 1:1 ratio, implanted intraoperatively."
      },
      "Participants": {
        "score": 2,
        "evidence": "patients undergoing abdominoplasty"
      },
      "Intervention": {
        "score": 2,
        "evidence": "patients undergoing abdominoplasty were randomized to three 100 mg bupivacaine implants or three placebo collagen implants"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study examined the efficacy and safety of the bupivacaine implant (300 mg) compared with placebo for postsurgical pain after abdominoplasty."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Primary outcome: the analgesic effect of the bupivacaine implants through 24 hours postsurgery, measured by the sum of time-weighted pain intensity (SPI24)."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "patients undergoing abdominoplasty were randomized"
      },
      "Blinding": {
        "score": 3,
        "evidence": "In this double-blind, placebo-controlled study"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "The bupivacaine implant patients (n=181) reported statistically significant lower SPI24"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The bupivacaine implant patients (n=181) reported statistically significant lower SPI24"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The bupivacaine implant patients (n=181) reported statistically significant lower SPI24 (mean (SD) SPI24=102 (43), 95% CI 95 to 109) compared with placebo patients (n=184; SPI24=117 (45), 95% CI 111 to 123, p=0.002)."
      },
      "Harms": {
        "score": 1,
        "evidence": "The only adverse event occurring in \u22655% of patients and for which proportion INL-001 >placebo was back pain (7.7% vs 7.6%)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration number: NCT04785625 ."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 21,
    "max_score": 25
  },
  "model": "gpt-4o"
}